Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 4Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Myasthenia Gravis 1Leukemia 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

rozanolixizumab 5zilucoplan 4eculizumab 4Rituximab 4Immunoglobulins, Intravenous 4efgartigimod alfa 3Tacrolimus 3Mycophenolic Acid 3Hizentra 3HBM9161 3Data Collection 2Azathioprine 2tofacitinib 1telitacicept 1ravulizumab 1iscalimab 1gamma-Globulins 1apraclonidine 1Thymectomy 1Telemedicine 1Sugammadex 1Sodium Chloride 1Pyridostigmine Bromide 1Prednisone 1Prednisolone 1Plasmapheresis 1Plasma Exchange 1Neurofeedback 1Neostigmine 1Muscle Stretching Exercises 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myasthenia Gravis × Pyridostigmine Bromide × Clear all
NCT07154095 2025-09-04

A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period, Crossover Study Comparing the Pharmacokinetics and Safety of Pyridostigmine Sustained-Release and Immediate-Release Tablets Following Single and Multiple Doses in Healthy Chinese Participants

West China Second University Hospital

Phase 1 Completed
40 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡